




Fig. 1

2/62




Fig. 2




Fig. 3

4/62




Fig. 4

5/62




Fig. 5

6/62




Fig. 6

7/62




Fig. 7

8/62




Fig. 8

9/62




Fig. 9

10/62





Fig. 10

11/62

(Normal vs. Diabetic) Vs. (Diabetic T1 vs. Diabetic)



Compare the unique edges of **Normal** in the normal vs. disease delta network with the unique edges of **Disease T1** in the disease vs. disease T1 delta network. Edges in the intersection of normal and disease T1 are disease edges that were restored to normal when treated with T1.

Fig. 11

12/62




Fig. 12

13/62




Fig. 13




Fig. 14

15/62




Fig. 15

16/62




Fig. 16

17/62




Fig. 17

18/62




Fig. 18

19/62




Fig. 19

20/62





Fig. 20




Fig. 21-1




Fig. 21-2




Fig. 22

24/62




Fig. 23

25/62





Fig. 24

26/62




Fig. 25

27/62




Fig. 26

28/62




Fig. 27




Fig. 28

30/62





Fig. 29

31/62

Delta-Delta Networks

DD_NG.vs.HG.vs.HGT1.cys

 $[NG \text{ vs. } HG] \text{ vs. } [HG \text{ vs. } HGT1]$

**Fig. 30**

32/62




Fig. 31

33/62




Fig. 32

34/62




Fig. 33




Fig. 34

36/62





Fig. 35

37/62




Fig. 36A




Fig. 36B

38/62

XFAssay_922011_1745.xls




Fig. 37A




Fig. 37B

39/62




Fig. 38

40/62




Fig. 39

41/62





Fig. 40

42/62

"Multi-Proteomics" techniques to elucidate enzyme/kinase activity



Applying "Multi-Proteomics" techniques to elucidate enzyme/kinase activity. Integration of multiple proteomics datasets generated from *in-vitro* model provides a unique system to understand causal relationship between enzymes/kinases and their metabolites/ substrates in the context of global changes in cellular proteome.

Fig. 41A

43/62




Fig. 41B

44/62






Fig. 42


45/62

Significant decrease in PGK1 activity not protein expression in HepG2 treated with Sorafenib.

**Fig. 43**

Significant decrease in LDHA activity in HepG2 treated with Sorafenib.

**Fig. 44**



47/62




Fig. 46

48/62




Fig. 47

49/62




Fig. 48




Fig. 49

50/62




Fig. 50




Fig. 51

51/62




Fig. 52A




Fig. 52B

52/62




Fig. 53A




Fig. 53B




Fig. 53C

SUBSTITUTE SHEET (RULE 26)

54/62




Fig. 54A




Fig. 54B




Fig. 54C




Fig. 55




Fig. 56

57/62




Fig. 57A




Fig. 57B

58/62




Fig. 58A




Fig. 58B

59/62




Fig. 58C




Fig. 58D

60/62




Fig. 59A

61/62




Fig. 59B

62/62




Fig. 59C